A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study

MLA

Khanna, Dinesh, et al. “A Phase II Study of Avenciguat, a Novel Soluble Guanylate Cyclase Activator, in Patients with Systemic Sclerosis: Study Design and Rationale of the VITALISScE™ Study.” Journal of Scleroderma and Related Disorders, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1177/23971983241291923.

APA

Khanna, D., de Vries-Bouwstra, J., Hoffmann-Vold, A.-M., Kuwana, M., Low, A. H. L., Proudman, S., Flack, M., Kukreja, A., Fagan, N., & Distler, O. (2024). A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study. Journal of Scleroderma and Related Disorders, Preprints. https://doi.org/10.1177/23971983241291923

Chicago

Khanna, Dinesh, Jeska de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, Masataka Kuwana, Andrea Hsiu Ling Low, Susanna Proudman, Mary Flack, Anjli Kukreja, Nora Fagan, and Oliver Distler. 2024. “A Phase II Study of Avenciguat, a Novel Soluble Guanylate Cyclase Activator, in Patients with Systemic Sclerosis: Study Design and Rationale of the VITALISScE™ Study.” Journal of Scleroderma and Related Disorders, no. Preprints (January). doi:10.1177/23971983241291923.